Business Context and Reporting Period
This Form 6-K filing by Biodexa Pharmaceuticals Plc covers the month of June 2025, with the report dated June 13, 2025. The filing serves to disclose corporate governance changes approved by shareholders at a general meeting held on June 11, 2025.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is non-financial in nature and focuses exclusively on corporate structural updates.
Material Changes
- Share Nominal Value Reduction: Shareholders approved a change in the nominal value of the Company's ordinary shares from £0.00005 per share to £0.000001 per share.
- Articles of Association: New Articles of Association were adopted to implement the nominal value change.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, operational risks, contingencies, or unusual items. The document strictly reports the adoption of the New Articles and their incorporation by reference into existing registration statements (Form S-8 and Form F-3).
Key Facts for Investor Verification
- Verify the effective date of the nominal share value reduction from £0.00005 to £0.000001.
- Confirm the impact of the nominal value change on the Company's share capital and accounting treatment.
- Review the attached Exhibit 1.1 (New Articles of Association) for any additional governance provisions beyond the nominal value adjustment.